Showing results (131-140 of 219) with videos related to
Sort By:
Pageof 22
Cardiology and Therapy|August 20, 2014
Medical Costs of Oral Anticoagulants vs Warfarin for Atrial Fibrillation Patients with Different Stroke RisksSteve Deitelzweig, Alpesh Amin, Yonghua Jing, et al.Plos One|March 19, 2014
Glycogen synthase isoforms in Synechocystis sp. PCC6803: identification of different roles to produce glycogen by targeted mutagenesisSang-Ho Yoo, Byung-Hoo Lee, Youyoun Moon, et al.Journal of Agricultural and Food Chemistry|March 18, 2011
Structural characterization of Peruvian carrot (Arracacia xanthorrhiza) starch and the effect of annealing on its semicrystalline structureThais S Rocha, Verena A G Cunha, Jay-Lin Jane, et al.International Journal of Biological Macromolecules|June 14, 2017
Effects of adding corn oil and soy protein to corn starch on the physicochemical and digestive properties of the starchXu Chen, Xiao-Wei He, Bin Zhang, et al.Academic Radiology|September 18, 2016
Clinical Decision Support at the Point-of-Order Entry: An Education Simulation Pilot with Medical StudentsMarc H Willis, L Alexandre Frigini, Jay Lin, et al.Journal of Managed Care & Specialty Pharmacy|April 2, 2014
Health care burden of dyspepsia among nonvalvular atrial fibrillation patientsMichael H Kim, Kelly F Bell, Dinara Makenbaeva, et al.Journal of Medical Economics|March 28, 2012
Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trialsSteve Deitelzweig, Alpesh Amin, Yonghua Jing, et al.Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|October 11, 2013
Comparison of Medical Costs of Patients With Atrial Fibrillation Unsuitable for Warfarin Treatment With Apixaban or Aspirin Based on AVERROES TrialAlpesh Amin, Steve Deitelzweig, Yonghua Jing, et al.Journal of Medical Economics|July 23, 2013
Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trialsSteve Deitelzweig, Alpesh Amin, Yonghua Jing, et al.Journal of Thrombosis and Thrombolysis|January 31, 2014
Estimation of the impact of warfarin's time-in-therapeutic range on stroke and major bleeding rates and its influence on the medical cost avoidance associated with novel oral anticoagulant use-learnings from ARISTOTLE, ROCKET-AF, and RE-LY trialsAlpesh Amin, Steve Deitelzweig, Yonghua Jing, et al.Pageof 22